Elite Pharmaceuticals Inc
OTC:ELTP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Elite Pharmaceuticals Inc
OTC:ELTP
|
US |
|
Yunnan Botanee Bio-Technology Group Co Ltd
SZSE:300957
|
CN |
|
Kalbe Farma Tbk PT
IDX:KLBF
|
ID |
|
I
|
Incap Oyj
OMXH:ICP1V
|
FI |
|
B
|
Bactiquant A/S
CSE:BACTIQ
|
DK |
|
Cardno Ltd
ASX:CDD
|
AU |
|
N
|
Neodecortech SpA
MIL:NDT
|
IT |
|
Kansai Paint Co Ltd
TSE:4613
|
JP |
Elite Pharmaceuticals Inc
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 43 full-time employees. The company went IPO on 2014-02-20. The firm is principally engaged in the development and manufacture of oral, controlled-release products. The firm develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets (either on its own or by license to other companies) generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA) for generic products and New Drug Applications (NDA) for branded products. Elite owns, licenses and contract manufactures products, including Phentermine HCl 37.5mg tablets , Phendimetrazine Tartrate 35mg tablets, Naltrexone HCl 50mg tablets, Isradipine 2.5mg and 5mg capsules, Oxycodone HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, among others.
Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. The company is headquartered in Northvale, New Jersey and currently employs 43 full-time employees. The company went IPO on 2014-02-20. The firm is principally engaged in the development and manufacture of oral, controlled-release products. The firm develops and manufactures generic products, products using controlled-release drug technology, products utilizing abuse deterrent technologies, and it develops and markets (either on its own or by license to other companies) generic controlled-release and abuse deterrent pharmaceutical products. Its segments include Abbreviated New Drug Applications (ANDA) for generic products and New Drug Applications (NDA) for branded products. Elite owns, licenses and contract manufactures products, including Phentermine HCl 37.5mg tablets , Phendimetrazine Tartrate 35mg tablets, Naltrexone HCl 50mg tablets, Isradipine 2.5mg and 5mg capsules, Oxycodone HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets, Trimipramine Maleate Immediate Release 25mg, 50mg and 100mg capsules, among others.
Record Revenue: Elite reported Q3 revenue of $31.6 million, up 120% year-over-year, and surpassed last year's full-year revenue in just 9 months.
Profitability Surge: Gross profit more than doubled to $13 million for the quarter, and income from operations jumped to $9 million, up 721% from last year’s Q3.
Growth Drivers: Expansion of the product line, strong performance from key generics like Lisdex (70% market share), and broader customer reach under the Elite label drove results.
Cash and Balance Sheet: Operating cash flow reached $14.6 million for 9 months, working capital climbed 83% year-to-date to $84 million, and the balance sheet remains strong with low debt.
Guidance and Outlook: Management expects FY26 revenue of $130–$140 million, citing ongoing growth and a robust R&D pipeline, with methadone and ropinirole launches on deck.
M&A and Uplisting: Elite’s top priority is M&A, but uplisting to NASDAQ remains an option if suitable deals do not materialize.
